SOAT1 and myelofibrosis: It is known that JAK–STAT pathways are essential for cytokine-mediated hematopoiesis [12]; that is the reason why thrombocytopenia and anemia are one of the major adverse effects of ruxolitinib that have been observed in other studies in myelofibrosis.